- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.04. | Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst | 1 | Seeking Alpha | ||
| 03.04. | Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 26.03. | Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, "VOQUEZNA Can Kick Some Acid" | 3 | GlobeNewswire (USA) | ||
| 08.03. | Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript | 3 | Insider Monkey | ||
| 07.03. | Phathom Pharmaceuticals, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 07.03. | Phathom Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 07.03. | Phathom Pharmaceuticals Non-GAAP EPS of -$0.80 beats by $0.20, revenue of $0.68M beats by $0.3M | 1 | Seeking Alpha | ||
| 07.03. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.03. | Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | 92 | GlobeNewswire (Europe) | Launched VOQUEZNA® (vonoprazan) tablets in November 2023 for the treatment of Erosive GERD (gastroesophageal reflux disease), achieving net revenues of $0.7 million for the fourth quarter Early physician... ► Artikel lesen | |
| 06.03. | Preview: Phathom Pharmaceuticals' Earnings | 2 | Benzinga.com | ||
| 29.02. | Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024 | 2 | GlobeNewswire (USA) | ||
| 13.02. | Phathom Pharmaceuticals gains Express Scripts formulary placement | 6 | Investing.com | ||
| 13.02. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.01. | Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference | 1 | GlobeNewswire (USA) | ||
| 25.01. | Phathom Pharmaceuticals says Takeda Pharmaceutical sold 3.7M shares | 10 | Seeking Alpha | ||
| 05.01. | "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales | 5 | Benzinga.com | ||
| 14.12.23 | Phathom Pharmaceuticals expands existing loan and security deal with Hercules Capital | 12 | Seeking Alpha | ||
| 14.12.23 | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.12.23 | Phathom Pharma heartburn drug undergoes FDA review | 2 | Seeking Alpha | ||
| 06.12.23 | Phathom Pharmaceuticals: FDA Accepts For Filing NDA For VOQUEZNA | 1 | RTTNews |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,535 | -5,25 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,824 | -4,19 % | EQS-News: Defence Therapeutics Inc.: Der AccuTOX ARM-002-Impfstoff zur Krebsbekämpfung führt zu einer hochwirksamen Antigenpräsentation | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
DER ACCUTOX ARM-002-IMPFSTOFF ZUR KREBSBEKÄMPFUNG FÜHRT ZU EINER HOCHWIRKSAMEN ANTIGENPRÄSENTATION... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,990 | 0,00 % | Is a Giant Short Squeeze in Ginkgo Bioworks (DNA) Stock? | ||
| BEAM THERAPEUTICS | 22,050 | +3,13 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,030 | +1,98 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,200 | 0,00 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| ARCTURUS THERAPEUTICS | 26,630 | +0,30 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,848 | 0,00 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,830 | +0,46 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,740 | +0,07 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,370 | +1,70 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,260 | +1,62 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,600 | +2,99 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 2,850 | 0,00 % | Bio-Path files to sell 484K shares of common stock for holders | ||
| BIOMEA FUSION | 10,750 | 0,00 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
PHATHOM PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,85 % bei einem Aktienkurs von 9,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
